JOE Society for Endocrinology Archive
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Journal of Endocrinology (1998) 158, R1-R5       DOI: 10.1677/joe.0.158R001
© 1998 Society for Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ono, K
Right arrow Articles by Nagata, N
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ono, K
Right arrow Articles by Nagata, N
Journal of Endocrinology, Vol 158, Issue 3, R1-R5
Copyright © 1998 by Society for Endocrinology

Articles

Important role of EP4, a subtype of prostaglandin (PG) E receptor, in osteoclast-like cell formation from mouse bone marrow cells induced by PGE2

K Ono, T Akatsu, T Murakami, M Nishikawa, M Yamamoto, N Kugai, K Motoyoshi, and N Nagata


Of various PGs, PGE1 and PGE2 are shown to be the most potent stimulators of osteoclastogenesis in vitro. PGE receptors have been classified into four subtypes, EP1-EP4. Little is known about PGE receptors functioning in bone cells. In this study, using mouse marrow culture, we investigated which PGE receptors are important in osteoclast-like cell (OCL) formation induced by PGE. 11-deoxy-PGE1 (EP2, EP3 and EP4 agonist) stimulated OCL formation potently. Butaprost (EP2 agonist) stimulated it slightly, while sulprostone (EP1 and EP3 agonist) and ONO-AP-324-01 (EP3 agonist) did not. AH23848B (EP4 antagonist) inhibited PGE2-induced OCL formation in a dose-dependent manner. The expression of EP4 mRNA in mouse bone marrow was confirmed by RT-PCR. The results indicate an important role of EP4 in PGE2-induced OCL formation in marrow cultures and suggest therapeutic potential of EP4 antagonists in some clinical conditions with accelerated bone resorption.


This article has been cited by other articles:


Home page
 IBMS BoneKEyHome page
L. G. Raisz
Selective Prostaglandin Agonists as Anabolic Agents
IBMS BoneKEy, July 1, 2006; 3(7): 15 - 20.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Tintut, F. Parhami, A. Tsingotjidou, S. Tetradis, M. Territo, and L. L. Demer
8-Isoprostaglandin E2 Enhances Receptor-activated NFkappa B Ligand (RANKL)-dependent Osteoclastic Potential of Marrow Hematopoietic Precursors via the cAMP Pathway
J. Biol. Chem., April 12, 2002; 277(16): 14221 - 14226.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. Machwate, S. Harada, C. T. Leu, G. Seedor, M. Labelle, M. Gallant, S. Hutchins, N. Lachance, N. Sawyer, D. Slipetz, et al.
Prostaglandin Receptor EP4 Mediates the Bone Anabolic Effects of PGE2
Mol. Pharmacol., July 1, 2001; 60(1): 36 - 41.
[Abstract] [Full Text]

Home page
 J. Am. Coll. Nutr.Home page
B. A. Watkins and M. F. Seifert
Conjugated Linoleic Acid and Bone Biology
J. Am. Coll. Nutr., August 1, 2000; 19(4): 478S - 486.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
M. D. Breyer and R. M. Breyer
Prostaglandin E receptors and the kidney
Am J Physiol Renal Physiol, July 1, 2000; 279(1): F12 - F23.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the Society for Endocrinology.